BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Oculus Innovative Sciences, Inc. 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

 Key Statistics


Email: hr@oculusis.com
Ownership:

Web Site: Oculus Innovative Sciences, Inc.
Employees:
Symbol: OCLS
 









 Company News
Oculus Innovative Sciences, Inc. (OCLS) Reports Revenues Of $3.4 Million And Net Loss Of $70,000 For First Quarter Of Fiscal 2015 8/8/2014 8:50:21 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal First Quarter 2015 Financial Results And Conference Call 7/24/2014 10:35:52 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal Fourth Quarter 2014 Financial Results And Conference Call 7/9/2014 9:14:50 AM
Oculus Innovative Sciences, Inc. (OCLS) Reports Revenues Of $2.9 Million And Net Income Of $7.5 Million For Fourth Quarter Of Fiscal 2014 Primarily Due To Accounting Treatment Of Ruthigen IPO Transaction 6/13/2014 8:08:01 AM
Oculus Innovative Sciences, Inc. (OCLS) Sciences Announces Fiscal Fourth Quarter 2014 Financial Results And Conference Call 5/29/2014 8:54:07 AM
Oculus Innovative Sciences, Inc. (OCLS)' Partner, More Pharma Corporation, Launches Microcyn®-Based Oral And Throat Infection Treatment Product In Mexico 4/22/2014 8:54:54 AM
Oculus Innovative Sciences, Inc. (OCLS) Receives "Strong Consensus" Rating For Use With Kinetic Concepts, Inc. (KCI)' Negative Pressure Wound Therapy With Instillation 4/9/2014 8:00:55 AM
Oculus Innovative Sciences, Inc. (OCLS) Shakes Up Board Following Ruthigen IPO 4/2/2014 9:23:36 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Appointment Of Sharon Barbari To Its Board Of Directors 3/27/2014 9:53:31 AM
Oculus Innovative Sciences, Inc. (OCLS) To Raise $1.35 Million In Registered Direct Offering 2/24/2014 8:59:25 AM
12345678910...